Toca 511基因转移联合前药5-氟胞嘧啶治疗在小鼠胶质瘤模型中促进持久抗肿瘤免疫
研究在小鼠胶质瘤模型中用流式细胞术监测Toca 511联合5-氟胞嘧啶(5-FC)治疗后肿瘤内免疫细胞浸润变化,发现免疫抑制性髓系细胞减少、CD4+ T细胞向非Th2/Th17极化及干扰素γ表达CD8+ T细胞扩增,与皮下Tu-2449肿瘤清除及T细胞依赖性抗再次攻击保护相关。
要点
- Toca 511联合5-FC使肿瘤内免疫抑制性髓系细胞减少。
- 随后CD4+ T细胞偏离Th2/Th17极化,干扰素γ表达CD8+ T细胞扩增。
- 免疫改变与Tu-2449皮下肿瘤清除及T细胞依赖性保护相关。
核心结论
- Toca 511联合5-FC治疗在肿瘤部位集中起效,直接引起肿瘤细胞死亡并改变免疫细胞浸润,形成更利于建立T细胞介导抗肿瘤免疫应答的肿瘤微环境。
研究设计与样本
- 研究在B6C3F1小鼠皮下Tu-2449胶质瘤模型中给予Toca 511联合5-FC治疗,并用流式细胞术监测和表征肿瘤内免疫细胞浸润。
主要发现
- 荷瘤动物经Toca 511联合5-FC治疗后肿瘤内免疫细胞群体发生改变,产生抗肿瘤免疫保护。
- 免疫抑制性细胞减少仅限于髓系来源的免疫抑制细胞。
- 免疫抑制细胞减少在时间上先于第二事件,即CD4+ T细胞群体偏离Th2和Th17极化,同时干扰素γ表达CD8+ T细胞扩增。
- 免疫改变与Tu-2449皮下肿瘤清除及T细胞依赖性保护免受后续肿瘤攻击相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Toca 511 (vocimagene amiretrorepvec) is a retroviral replicating vector encoding an optimized yeast cytosine deaminase (CD). Tumor-selective expression of CD converts the prodrug, 5-fluorocytosine (5-FC), into the active chemotherapeutic, 5-fluorouracil (5-FU). This therapeutic approach is being tested in a randomized phase II/III trial in recurrent glioblastoma and anaplastic astrocytoma (NCT0241416). The aim of this study was to identify the immune cell subsets contributing to antitumor immune responses following treatment with 5-FC in Toca 511-expressing gliomas in a syngeneic mouse model. METHODS: Flow cytometry was utilized to monitor and characterize the immune cell infiltrate in subcutaneous Tu-2449 gliomas in B6C3F1 mice treated with Toca 511 and 5-FC. RESULTS: Tumor-bearing animals treated with Toca 511 and 5-FC display alterations in immune cell populations within the tumor that result in antitumor immune protection. Attenuated immune subsets were exclusive to immunosuppressive cells of myeloid origin. Depletion of immunosuppressive cells temporally preceded a second event which included expansion of T cells which were polarized away from Th2 and Th17 in the CD4+ T cell compartment with concomitant expansion of interferon gamma-expressing CD8+ T cells. Immune alterations correlated with clearance of Tu-2449 subcutaneous tumors and T cell-dependent protection from future tumor challenge. CONCLUSIONS: Treatment with Toca 511 and 5-FC has a concentrated effect at the site of the tumor which causes direct tumor cell death and alterations in immune cell infiltrate, resulting in a tumor microenvironment that is more permissive to establishment of a T cell mediated antitumor immune response.
引用
- Mitchell LA, Lopez Espinoza F, Mendoza D, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 2017. PMID: 28387849. doi:10.1093/neuonc/nox037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。